Navigation Links
Glutamate: Too much of a good thing in schizophrenia?
Date:10/27/2008

Philadelphia, PA, October 27, 2008 Is schizophrenia a disorder of glutamate hyperactivity or hypoactivity? While the predominant hypothesis for many years was that schizophrenia was a glutamate deficit disorder, there is growing evidence of glutamate hyperactivity as well. The study by Karlsson et al., appearing in the November 1st issue of Biological Psychiatry, reinforces this point with new data about the impact of deleting the gene for the glutamate transporter EAAT1. EAAT1, implicated in schizophrenia, plays a critical role in inactivating glutamate by removing it from the synaptic and extracellular spaces. The authors demonstrate that these "knockout" animals show increased responses to the NMDA glutamate receptor antagonist, MK-801. This drug causes the release of more glutamate into the synapse in the frontal cortex. This effect of MK-801 is reduced by a group II metabotropic glutamate receptor agonist, which reduces glutamate release. Dr. Andrew Holmes, corresponding author, further discusses their findings, "Our study adds a new twist to [glutamate] research by showing that genetically disrupting a major regulator of glutamate's ability to communicate between nerve cells produces certain 'schizophrenia-like' features in mice and, moreover, that these abnormalities can be corrected by a highly promising new class of glutamate-targeting antipsychotic treatments." In fact, this class of drugs has already shown some preliminary efficacy in its ability to treat individuals suffering from schizophrenia.

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments: "The NMDA receptor antagonist model and the EAAT1 knockout animal push us to take a fresh look at the obstacles to treating cognitive impairments associated with schizophrenia, in other words, optimizing their cortical network function. This new look can lead us to drugs that would have been completely surprising as recently as 10 years ago, such as the group II metabotropic glutamate receptor agonists."

Dr. Holmes does note that further research is warranted, stating, "What is now needed is more research to get a better handle on how disrupting this gene affects the brain's neural wiring and molecular signaling pathways to produce the symptoms of schizophrenia." This finding could ultimately help scientists develop new or improved treatments for this schizophrenia.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. MSAs Next-Generation Breathing Apparatus for Firefighters First to Receive Full NFPA Approval
2. Wanting a bite of everything: Hungry people crave more variety
3. Non-Stick Gum Something to Chew On
4. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
5. Something Wicked! This Way Comes: Elvira Hosts Halloween Fashion Show and Fundraiser Benefiting AIDS Healthcare Foundation
6. The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR
7. The USDA E. coli Loophole in Ground Beef: Much Ado About Nothing
8. Childhood sleep-disordered breathing disproportionately affects obese and African-Americans
9. Its not just a kid thing: Fluoridated tap water benefits older adults even more
10. Patients wonder, Could this be something serious?
11. Honey Beats Meds at Soothing Kids Cough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... IN (PRWEB) , ... December 06, 2016 , ... ... benefits advisory organization, is proud to announce it has added CXC Solutions (CXC) ... benefits management solutions. These solutions are tailored to help benefits advisors reduce ...
(Date:12/6/2016)... ... 2016 , ... METTLER TOLEDO has launched its online ... papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user manuals, ... webinars and videos available online, visit the METTLER TOLEDO Expertise Library . ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... fascinating recount of a powerful woman's story of sacrifice and enlightenment. ... of published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LONDON , Dec. 5, 2016 Spain ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market ... Spain Glaucoma Surgery Devices market. The report provides value, ... average prices (USD) within market segements - Canaloplasty Micro ... provides company shares and distribution shares data for each ...
(Date:12/5/2016)... , Dec. 5, 2016  Cornerstone Pharmaceuticals, Inc., ... presented data from two Phase I trials evaluating ... the 58th annual meeting of the American Society ... California . The two datasets show encouraging ... myeloid leukemia (AML) and T-cell non-Hodgkin,s lymphoma (T-cell ...
(Date:12/5/2016)... 2016  Pennsylvania Physician General Dr. Rachel Levine ... Gary Tennis today filled prescriptions for naloxone, a ... York to demonstrate how anyone ... as a prescription to acquire naloxone at any pharmacy ... remember that any Pennsylvanian can walk up to their ...
Breaking Medicine Technology: